Pamela T Beck

US Patent:

6713604, Mar 30, 2004

Filed:

May 8, 1996

Appl. No.:

08/646558

Inventors:

Timothy P. Kogan - Sugar Land TX
Kaijun Ren - Sugar Land TX
Peter Vanderslice - Houston TX
Pamela J. Beck - Houston TX

Assignee:

Texas Biotechnology Corporation - Houston TX

International Classification:

C07K 1600

US Classification:

530317, 514 11, 514 9, 514 2

Abstract:

The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.

US Patent:

55103324, Apr 23, 1996

Filed:

Jul 7, 1994

Appl. No.:

8/271830

Inventors:

Timothy P. Kogan - Sugar Land TX
Kaijun Ren - Sugar Land TX
Peter Vanderslice - Houston TX
Pamela J. Beck - Houston TX

Assignee:

Texas Biotechnology Corporation - Houston TX

International Classification:

A61K 3800
C07K 100

US Classification:

514 14

Abstract:

The present invention is directed to an isolated and purified peptide comprising the LDV domain of the CSI peptide sequence or single amino acid substitutent analog thereof. A preferred peptide has the amino acid residue sequences shown in SEQ ID NOs:8-14, 17-23, 25, 28, and 51. The present invention is further directed to a process of inhibiting the binding of. alpha. sub. 4. beta. sub. 1 integrin to a protein such as VCAM-1 or fibronectin comprising exposing a cell that expresses. alpha. sub. 4. beta. sub. 1 integrin to the protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition comprising a peptide of SEQ ID NO:8-102.

US Patent:

60873302, Jul 11, 2000

Filed:

Apr 13, 1998

Appl. No.:

9/059111

Inventors:

Timothy P. Kogan - Sugar Land TX
Kaijun Ren - Sugar Land TX
Peter Vanderslice - Houston TX
Pamela J. Beck - Houston TX

Assignee:

Texas Biotechnology Corporation - Houston TX

International Classification:

A61K 3812
C07K 764

US Classification:

514 11

Abstract:

The present invention is directed to an isolated and purified cyclic peptide of from 5 to about 13 residues modeled after a portion of the CS1 peptide. A peptide of this invention preferably has the amino acid residue sequence of SEQ ID NO:2-14 or 16-42. The present invention is further directed to a process of selectively inhibiting the binding of. alpha. sub. 4. beta. sub. 1 integrin to a protein such as VCAM-1, fibronectin or invasin. In accordance with that process, a cell that expresses. alpha. sub. 4. beta. sub. 1 integrin is exposed to that protein in the presence of an effective inhibiting amount of such a peptide. The present invention is still further directed to a pharmaceutical composition containing a physiologically acceptable carrier and a cyclic peptide of the invention.

US Patent:

56229372, Apr 22, 1997

Filed:

May 1, 1996

Appl. No.:

8/641341

Inventors:

Timothy P. Kogan - Sugar Land TX
Brian Dupre - Houston TX
Huong Dao - Houston TX
Pamela J. Beck - Houston TX

Assignee:

Texas Biotechnology Corporation - Houston TX

International Classification:

A61K 3170
C07H 1500

US Classification:

514 25

Abstract:

This invention relates to compounds that inhibit the binding of E-selectin or P-selectin to sialyl-Lewis. sup. x or sialyl-Lewis. sup. a presented on a cell surface having the general structure: ##STR1## This invention also relates to methods of inhibiting the binding of E-selectin or P-selectin to sialyl-Lewis. sup. x or sialyl-Lewis. sup. a presented on a cell surface using said compounds and to pharmaceutically active compositions comprising compounds that inhibit the binding of E-selectin to sialyl-Lewis. sup. x and to methods of treatment of septic shock, ARDS, Crohn's disease, chronic inflammatory diseases, such as psoriasis and rheumatoid arthritis, and reperfusion injuries that occurs following heart attacks, strokes and organ transplants and to the treatment of cancer.

US Patent:

54440505, Aug 22, 1995

Filed:

Apr 29, 1994

Appl. No.:

8/235293

Inventors:

Timothy P. Kogan - Sugar Land TX
Brian Dupre - Houston TX
Ian L. Scott - Houston TX
Karin Keller - Houston TX
Huong Dao - Houston TX
Pamela J. Beck - Houston TX

Assignee:

Texas Biotechnology Corporation - Houston TX

International Classification:

A61K 3170
C07H 1520

US Classification:

514 25

Abstract:

This invention relates to compounds that inhibit the binding of E-selectin and/or P-selectin to sialyl-Lewis. sup. x or sialyl-Lewis. sup. a presented on a cell surface having the general structure ##STR1## wherein X is selected from the group consisting of --(CH. sub. 2). sub. n CO. sub. 2 H, --O(CH. sub. 2). sub. m CO. sub. 2 H, --(CH. sub. 2). sub. n O(CH. sub. 2). sub. m CO. sub. 2 H, --CONH(CH. sub. 2). sub. m CO. sub. 2 H, --CH(OZ)(CO. sub. 2 H), --CH(Z)(CO. sub. 2 H), --(CH. sub. 2). sub. n SO. sub. 3 H, --(CH. sub. 2). sub. n PO. sub. 3 D. sub. 1 D. sub. 2, --NH(CH. sub. 2). sub. m CO. sub. 2 H, --CONH(CHR. sub. 6)CO. sub. 2 H, (1-H-tetrazolyl-5-alkyl-), and --OH; R. sub. 1 and R. sub. 2 are independently selected from the group consisting of hydrogen, alkyl, halogen, --OZ, --NO. sub. 2, --NH. sub. 2 and --NHZ; R. sub.